HIV-1 viral protein r: From structure to function

Future Virology

Volumn 5, Issue 5, 2010, Pages 607-625

  Fritz, Jolle V ^a   Briant, Laurence ^b   Mély, Yves ^c   Bouaziz, Serge ^d   De Rocquigny, Hugues ^c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d CNRS   (France)

Author keywords

apoptose; cell cycle; fluorescence; HIV; NMR; structure; Vpr

Indexed keywords

CELL PROTEIN; GAG PROTEIN; MEMBRANE PROTEIN; NUCLEIC ACID; VPR PROTEIN;

APOPTOSIS; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STIMULATION; CHROMATIN STRUCTURE; COMPLEX FORMATION; DNA REPAIR; HOST; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA INTERACTION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STRUCTURE; REVIEW; SEQUENCE ANALYSIS; VIRUS PARTICLE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77957307780     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.47     Document Type: Review

References (179)

1. Ogawa K, Shibata R, Kiyomasu T et al.: Mutational analysis of the human immunodeficiency virus Vpr open reading frame. J. Virol. 63(9), 4110-4114 (1989).
2. Tristem M, Marshall C, Karpas A, Hill F: Evolution of the primate lentiviruses: evidence from Vpx and Vpr. EMBO J. 11(9), 3405-3412 (1992).
3. Wong-Staal F, Chanda PK, Ghrayeb J: Human immunodeficiency virus: the eighth gene. AIDS Res. Hum. Retroviruses 3(1), 33-39 (1987).
4. Gras-Masse H, Ameisen JC, Boutillon C et al.: A synthetic protein corresponding to the entire Vpr gene product from the human immunodeficiency virus HIV-1 is recognized by antibodies from HIV-infected patients. Int. J. Pept. Protein Res. 36(3), 219-226 (1990).
5. Reiss P, Lange JM, De Ronde A et al.: Antibody response to viral proteins u (Vpu) and r (Vpr) in HIV-1-infected individuals. J. Acquir. Immune Defc. Syndr. 3(2), 115-122 (1990).
6. Levy DN, Refaeli Y, Macgregor RR, Weiner DB: Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 91(23), 10873-10877 (1994).
7. Andersen JL, Le Rouzic E, Planelles V: HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. Experiment. Mol. Pathol. 85(1), 2-10 (2008).
8. Romani B, Engelbrecht S: Human immunodeficiency virus type 1 Vpr: Functions and molecular interactions. J. Gen. Virol. 90 (Pt 8), 1795-1805 (2009).
9. Morellet N, Roques BP, Bouaziz S: Structure-function relationship of Vpr: biological implications. Curr. HIV Res. 7(2), 184-210 (2009). □□ Correlates the multiple activities of viral protein r (Vpr) with the different structural domains of the protein.
10. Planelles V, Benichou S: Vpr and its interactions with cellular proteins. Curr. Topics Microbiol. Immunol. 339, 177-200 (2009). □□ Recent review that presents the cellular partners recognized by Vpr to explain the effect of the protein on the cell cycle.
11. Fouchier RA, Meyer BE, Simon JH et al.: Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J. Virol. 72(7), 6004-6013 (1998). □□ First evidence that Vpr interacts with a protein of the nuclear pore complexes, suggesting a role for Vpr during the cellular traffic of the preintegration complex.
12. Le Rouzic E, Mousnier A, Rustum C et al.: Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin HCG1. J. Biol. Chem. 277(47), 45091-45098 (2002).
13. Bachand F, Yao XJ, Hrimech M, Rougeau N, Cohen EA: Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 Gag precursor. J. Biol. Chem. 274(13), 9083-9091 (1999).
14. Lu YL, Bennett RP, Wills JW, Gorelick R, Ratner L: A leucine triplet repeat sequence (lxx) 4 in p6Gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J. Virol. 69(11), 6873-6879 (1995).
15. Mahalingam S, Khan SA, Jabbar MA, Monken CE, Collman RG, Srinivasan A: Identification of residues in the N-terminal acidic domain of HIV-1 Vpr essential for virion incorporation. Virology 207(1), 297-302 (1995).
16. Lavallee C, Yao XJ, Ladha A, Gottlinger H, Haseltine WA, Cohen EA: Requirement of the pr55Gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles. J. Virol. 68(3), 1926-1934 (1994).
17. Cohen EA, Dehni G, Sodroski JG, Haseltine WA: Human immunodeficiency virus Vpr product is a virion-associated regulatory protein. J. Virol. 64(6), 3097-3099 (1990).
18. Paxton W, Connor RI, Landau NR: Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of Gag and mutational analysis. J. Virol. 67(12), 7229-7237 (1993).
19. Kondo E, Mammano F, Cohen EA, Gottlinger HG: The p6Gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J. Virol. 69(5), 2759-2764 (1995).
20. Bruns K, Fossen T, Wray V, Henklein P, Tessmer U, Schubert U: Structural characterization of the HIV-1 Vpr N terminus: evidence of cis/trans-proline isomerism. J. Biol. Chem. 278(44), 43188-43201 (2003).
21. Engler A, Stangler T, Willbold D: Solution structure of human immunodeficiency virus type 1 Vpr (13-33) peptide in micelles. Eur. J. Biochem. 268(2), 389-395 (2001).
22. Engler A, Stangler T, Willbold D: Structure of human immunodeficiency virus type 1 Vpr (34-51) peptide in micelle containing aqueous solution. Eur. J. Biochem. 269(13), 3264-3269 (2002).
23. Henklein P, Bruns K, Sherman MP et al.: Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G2 cell cycle arrest. J. Biol. Chem. 275(41), 32016-32026 (2000).
24. Luo Z, Butcher DJ, Murali R, Srinivasan A, Huang Z: Structural studies of synthetic peptide fragments derived from the HIV-1 Vpr protein. Biochem. Biophys. Res. Commun. 244(3), 732-736 (1998).
25. Morellet N, Bouaziz S, Petit jean P, Roques BP: NMR structure of the HIV-1 regulatory protein Vpr. J. Mol. Biol. 327(1), 215-227 (2003). □□ 3D structure of Vpr obtained by NMR showing the three well-defined α-helices mutually folded to form a central hydrophobic plateau surrounded by flexible N-and C-terminal domains.
26. 2O/trifluoroethanol. Comparison with the Vpr N-terminal (1-51) and C-terminal (52-96) domains. Eur. J. Biochem. 269(15), 3779-3788 (2002).
27. Wecker K, Roques BP: NMR structure of the (1-51) N-terminal domain of the HIV-1 regulatory protein Vpr. Eur. J. Biochem. 266(2), 359-369 (1999).
28. Bourbigot S, Beltz H, Denis J et al.: The C-terminal domain of the HIV-1 regulatory protein Vpr adopts an antiparallel dimeric structure in solution via its leucine-zipper-like domain. Biochem. J. 387 (Pt 2), 333-341 (2005).
29. Schuler W, Wecker K, de Rocquigny H, Baudat Y, Sire J, Roques BP: NMR structure of the (52-96) C-terminal domain of the HIV-1 regulatory protein Vpr: molecular insights into its biological functions. J. Mol. Biol. 285(5), 2105-2117 (1999).
30. Yao XJ, Mouland AJ, Subbramanian RA et al.: Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing jurkat T cells. J. Virol. 72(6), 4686-4693 (1998).
31. Blanco FJ, Jimenez MA, Pineda A, Rico M, Santoro J, Nieto JL: NMR solution structure of the isolated N-terminal fragment of protein-G b1 domain. Evidence of trifluoroethanol induced native-like β-hairpin formation. Biochemistry 33(19), 6004-6014 (1994).
32. Gooley PR, Mackenzie NE: Location of an α-helix in fragment 96-133 from bovine somatotropin by 1h NMR spectroscopy Biochemistry 27(11), 4032-4040 (1988).
33. Leist T, Thomas RM: Synthesis and physicochemical characterization of major fragments of human leucocyte interferon α 1. Biochemistry 23(12), 2541-2547 (1984).
34. Muhle-Goll C, Gibson T, Schuck P et al.: The dimerization stability of the HLH-LZ transcription protein family is modulated by the leucine zippers: a CD and NMR study of Tfeb and c-myc. Biochemistry 33(37), 11296-11306 (1994).
35. Nelson JW, Kallenbach NR: Persistence of the α-helix stop signal in the s-peptide in trifluoroethanol solutions. Biochemistry 28(12), 5256-5261 (1989).
36. Zhao LJ, Wang L, Mukherjee S, Narayan O: Biochemical mechanism of HIV-1 Vpr function. Oligomerization mediated by the N-terminal domain. J. Biol. Chem. 269(51), 32131-32137 (1994). □ First publication showing that the N-terminus of Vpr is required for Vpr oligomerization in vitro.
37. Jenkins Y, Pornillos O, Rich RL, Myszka DG, Sundquist WI, Malim MH: Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6 (Gag). J. Virol. 75(21), 10537-10542 (2001). (Pubitemid 32948090)
38. + T cells. J. Virol. 81(17), 8878-8890 (2007). □ Mutants of Vpr with reduced Vpr oligomerization and nuclear localization retain the ability to induce G2/M and cell death. Moreover, Vpr mutants with low G2/M potency were as cytotoxic as the wild-type.
39. Fritz JV, Didier P, Clamme JP et al.: Direct Vpr-Vpr interaction in cells monitored by two photon fluorescence correlation spectroscopy and fluorescence lifetime imaging. Retrovirology 5, 87 (2008).
40. Gaynor EM, Chen IS: Analysis of apoptosis induced by HIV-1 Vpr and examination of the possible role of the hhr23a protein. Exp. Cell Res. 267(2), 243-257 (2001).
41. Jacquot G, Le Rouzic E, David A et al.: Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages. Retrovirology 4(1), 84 (2007).
42. Forget J, Yao XJ, Mercier J, Cohen EA: Human immunodeficiency virus type 1 Vpr protein transactivation function: mechanism and identification of domains involved. J. Mol. Biol. 284(4), 915-923 (1998).
43. Singh SP, Tomkowicz B, Lai D et al.: Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr. J. Virol. 74(22), 10650-10657 (2000).
44. Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, Cohen EA: Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal α-helical structure in Vpr nuclear localization and virion incorporation. J. Virol. 69(11), 7032-7044 (1995).
45. Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR: Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J. Virol. 69(12), 7909-7916 (1995).
46. Mahalingam S, Khan SA, Murali R et al.: Mutagenesis of the putative α-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation. Proc. Natl Acad. Sci. USA 92(9), 3794-3798 (1995).
47. Mahalingam S, Ayyavoo V, Patel M, Kieber-Emmons T, Weiner DB: Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J. Virol. 71(9), 6339-6347 (1997).
48. Nie Z, Bergeron D, Subbramanian RA et al.: The putative α helix 2 of human immunodeficiency virus type 1 Vpr contains a determinant which is responsible for the nuclear translocation of proviral DNA in growth-arrested cells. J. Virol. 72(5), 4104-4115 (1998).
49. Subbramanian RA, Yao XJ, Dilhuydy H et al.: Human immunodeficiency virus type 1 Vpr localization: nuclear transport of a viral protein modulated by a putative amphipathic helical structure and its relevance to biological activity. J. Mol. Biol. 278(1), 13-30 (1998).
50. Wang L, Mukherjee S, Narayan O, Zhao LJ: Characterization of a leucine-zipper-like domain in Vpr protein of human immunodeficiency virus type 1. Gene 178 (1-2), 7-13 (1996).
51. Kamata M, Aida Y: Two putative α-helical domains of human immunodeficiency virus type 1 Vpr mediate nuclear localization by at least two mechanisms. J. Virol. 74(15), 7179-7186 (2000).
52. Zhou Y, Lu Y, Ratner L: Arginine residues in the C-terminus of HIV-1 Vpr are important for nuclear localization and cell cycle arrest. Virology 242(2), 414-424 (1998).
53. Sherman MP, De Noronha CM, Heusch MI, Greene S, Greene WC: Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr. J. Virol. 75(3), 1522-1532 (2001).
54. Macreadie IG, Castelli LA, Hewish DR, Kirkpatrick A, Ward AC, Azad AA: A domain of human immunodeficiency virus type 1 Vpr containing repeated H (S/F) RIG amino acid motifs causes cell growth arrest and structural defects. Proc. Natl Acad. Sci. USA 92(7), 2770-2774 (1995).
55. Berglez JM, Castelli LA, Sankovich SA, Smith SC, Curtain CC, Macreadie IG: Residues within the HFRIGC sequence of HIV-1 Vpr involved in growth arrest activities. Biochem. Biophys. Res. Commun. 264(1), 287-290 (1999).
56. Sawaya BE, Khalili K, Gordon J et al.: Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue r73. J. Virol. 74(10), 4877-4881 (2000).
57. Sawaya BE, Khalili K, Gordon J, Taube R, Amini S: Cooperative interaction between HIV-1 regulatory proteins tat and Vpr modulates transcription of the viral genome. J. Biol. Chem. 275(45), 35209-35214 (2000).
58. Sherman MP, De Noronha CM, Pearce D, Greene WC: Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G (2) cell cycle arrest. J. Virol. 74(17), 8159-8165 (2000).
59. Stewart SA, Poon B, Jowett JB, Chen IS: Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J. Virol. 71(7), 5579-5592 (1997).
60. Kobinger GP, Borsetti A, Nie Z et al.: Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins. J. Virol. 72(7), 5441-5448 (1998).
61. Muller B, Tessmer U, Schubert U, Krausslich HG: Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than Gag and is phosphorylated in infected cells. J. Virol. 74(20), 9727-9731 (2000).
62. Singh SP, Tungaturthi P, Cartas M et al.: Virion-associated HIV-1 Vpr: variable amount in virus particles derived from cells upon virus infection or proviral DNA transfection. Virology 283(1), 78-83 (2001).
63. Lai D, Singh SP, Cartas M, Murali R, Kalyanaraman VS, Srinivasan A: Extent of incorporation of HIV-1 Vpr into the virus particles is flexible and can be modulated by expression level in cells. FEBS Lett. 469 (2-3), 191-195 (2000).
64. Adamson CS, Freed EO: Human immunodeficiency virus type 1 assembly, release, and maturation. Advances Pharmacol. (San Diego, Calif.) 55, 347-387 (2007).
65. Selig L, Pages JC, Tanchou V et al.: Interaction with the p6 domain of the Gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. J. Virol. 73(1), 592-600 (1999).
66. Zhu H, Jian H, Zhao LJ: Identification of the 15frfg domain in HIV-1 Gag p6 essential for Vpr packaging into the virion. Retrovirology 1, 26 (2004).
67. Campbell EM, Perez O, Melar M, Hope TJ: Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell. Virology 360(2), 286-293 (2007).
68. Lampe M, Briggs JA, Endress T et al.: Double-labelled HIV-1 particles for study of virus-cell interaction. Virology 360(1), 92-104 (2007).
69. Mcdonald D, Vodicka MA, Lucero G et al.: Visualization of the intracellular behavior of HIV in living cells. J. Cell Biol. 159(3), 441-452 (2002).
70. Depienne C, Roques P, Creminon C et al.: Cellular distribution and karyophilic properties of matrix, integrase, and Vpr proteins from the human and simian immunodeficiency viruses. Exp. Cell Res. 260(2), 387-395 (2000).
71. Waldhuber MG, Bateson M, Tan J, Greenway AL, Mcphee DA: Studies with GFP-Vpr fusion proteins: induction of apoptosis but ablation of cell cycle arrest despite nuclear membrane or nuclear localization. Virology 313(1), 91-104 (2003).
72. Rudner L, Nydegger S, Coren LV, Nagashima K, Thali M, Ott DE: Dynamic fluorescent imaging of human immunodeficiency virus type 1 Gag in live cells by biarsenical labeling. J. Virol. 79(7), 4055-4065 (2005).
73. Fritz JV, Dujardin D, Godet J et al.: HIV-1 Vpr oligomerization and not that of Gag directs the interaction between Vpr and Gag. J. Virol. 84(3), 1585-1596 (2010). □□ Using cellular imaging, a direct interaction between Gag and Vpr was characterized. This work also shows that Gag controls the Vpr pathway during the assembly process.
74. Caly L, Jans DA, Piller SC: Proteolytic cleavage of HIV-1 GFP-Vpr fusions at novel sites within virions and living cells: concerns for intracellular trafficking studies. J. fluorescence 19(3), 567-573 (2008).
75. Gousset K, Ablan SD, Coren LV et al.: Real-time visualization of HIV-1 Gag trafficking in infected macrophages. PLoS Pathogens 4(3), e1000015 (2008).
76. Ono A, Freed EO: Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J. Virol. 78(3), 1552-1563 (2004).
77. Salgado GF, Marquant R, Vogel A et al.: Structural studies of HIV-1 Gag p6ct and its interaction with Vpr determined by solution nuclear magnetic resonance. Biochemistry 48(11), 2355-2367 (2009).
78. Salgado GF, Vogel A, Marquant R, Feller SE, Bouaziz S, Alves ID: The role of membranes in the organization of HIV-1 Gag p6 and Vpr: p6 shows high affinity for membrane bilayers which substantially increases the interaction between p6 and Vpr. J. Med. Chem. 52(22), 7157-7162 (2009).
79. de Rocquigny H, Petitjean P, Tanchou V et al.: The zinc fingers of HIV nucleocapsid protein NCp7 direct interactions with the viral regulatory protein Vpr. J. Biol. Chem. 272(49), 30753-30759. (1997).
80. Li MS, Garcia-Asua G, Bhattacharyya U, Mascagni P, Austen BM, Roberts MM: The Vpr protein of human immunodeficiency virus type 1 binds to nucleocapsid protein p7 in vitro. Biochem. Biophys. Res. Commun. 218(1), 352-355 (1996).
81. Tung HY, de Rocquigny H, Zhao LJ, Cayla X, Roques BP, Ozon R: Direct activation of protein phosphatase-2A0 by HIV-1 encoded protein complex NCp7:Vpr. FEBS Lett 401 (2-3), 197-201. (1997).
82. Sato A, Yoshimoto J, Isaka y et al.: Evidence for direct association of Vpr and matrix protein p17 within the HIV-1 virion. Virology 220(1), 208-212 (1996).
83. Accola MA, Ohagen A, Gottlinger HG: Isolation of human immunodeficiency virus type 1 cores: retention of Vpr in the absence of p6 (Gag). J. Virol. 74(13), 6198-6202 (2000).
84. Heinzinger NK, Bukinsky MI, Haggerty sa et al.: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc. Natl Acad. Sci. USA 91(15), 7311-7315 (1994).
85. + T cells. J. Exp. Med. 194(10), 1407-1419 (2001).
86. Bischerour J, Tauc P, Leh H, de Rocquigny H, Roques B, Mouscadet JF: The (52-96) C-terminal domain of Vpr stimulates HIV-1 in-mediated homologous strand transfer of mini-viral DNA. Nucleic Acids Res. 31(10), 2694-2702 (2003).
87. de Rocquigny H, Caneparo A, Delaunay T, Bischerour J, Mouscadet JF, Roques BP: Interactions of the C-terminus of viral protein r with nucleic acids are modulated by its N-terminus. Eur. J. Biochem. 267(12), 3654-3660 (2000).
88. Zhang S, Pointer D, Singer G, Feng Y, Park K, Zhao LJ: Direct binding to nucleic acids by Vpr of human immunodeficiency virus type 1. Gene 212(2), 157-166 (1998).
89. Bukrinsky M: A hard way to the nucleus. Mol. Med. (Cambridge, Mass.) 10 (1-6), 1-5 (2004).
90. Aida Y, Matsuda G: Role of Vpr in HIV-1 nuclear import: therapeutic implications. Curr. HIV Res. 7(2), 136-143 (2009).
91. Agostini I, Popov S, Li J, Dubrovsky L, Hao T, Bukrinsky M: Heat-shock protein 70 can replace viral protein r of HIV-1 during nuclear import of the viral preintegration complex. Exp. Cell Res. 259(2), 398-403 (2000).
92. Popov S, Rexach M, Ratner L, Blobel G, Bukrinsky M: Viral protein r regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J. Biol. Chem. 273(21), 13347-13352 (1998). (Pubitemid 28246910)
93. Kichler A, Pages JC, Leborgne C et al.: Efficient DNA transfection mediated by the C-terminal domain of human immunodeficiency virus type 1 viral protein r. J. Virol. 74(12), 5424-5431 (2000).
94. Coeytaux E, Coulaud D, Le Cam E, Danos O, Kichler A: The cationic amphipathic α-helix of HIV-1 viral protein r (Vpr) binds to nucleic acids, permeabilizes membranes, and efficiently transfects cells. J. Biol. Chem. 278(20), 18110-18116 (2003).
95. Piller SC, Ewart GD, Premkumar A, Cox GB, Gage PW: Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers. Proc. Natl Acad. Sci. USA 93(1), 111-115 (1996). □ Interaction of Vpr with lipids and formation of channels that could account for the cytotoxic effect of the protein.
96. Piller SC, Jans P, Gage PW, Jans DA: Extracellular HIV-1 virus protein r causes a large inward current and cell death in cultured hippocampal neurons: implications for AIDS pathology. Proc. Natl Acad. Sci. USA 95(8), 4595-4600 (1998).
97. Piller SC, Ewart GD, Jans DA, Gage PW, Cox GB: The amino-terminal region of Vpr from human immunodeficiency virus type 1 forms ion channels and kills neurons. J. Virol. 73(5), 4230-4238 (1999).
98. Vodicka MA, Koepp DM, Silver PA, Emerman M: HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev. 12(2), 175-185 (1998).
99. De Noronha CM, Sherman MP, Lin HW et al.: Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 294(5544), 1105-1108 (2001).
100. + lymphocytes. Apoptosis 2(1), 69-76 (1997). (Pubitemid 127508895)
101. Sabbah EN, Roques BP: Critical implication of the (70-96) domain of human immunodeficiency virus type 1 Vpr protein in apoptosis of primary rat cortical and striatal neurons. J. Neurovirol. 11(6), 489-502 (2005).
102. Huang MB, Weeks O, Zhao LJ, Saltarelli M, Bond VC: Effects of extracellular human immunodeficiency virus type 1 Vpr protein in primary rat cortical cell cultures. J. Neurovirol. 6(3), 202-220 (2000).
103. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424(6944), 99-103 (2003).
104. Harris RS, Bishop KN, Sheehy AM et al.: DNA deamination mediates innate immunity to retroviral infection. Cell 113(6), 803-809 (2003).
105. Turelli P, Guiguen F, Mornex JF, Vigne R, Querat G: Dutpase-minus caprine arthritisencephalitis virus is attenuated for pathogenesis and accumulates G-to-A substitutions. J. Virol. 71(6), 4522-4530 (1997).
106. Chen R, Wang H, Mansky LM: Roles of uracil-DNA glycosylase and dUTPase in virus replication. J. Gen. Virol. 83 (Pt 10), 2339-2345 (2002).
107. Willetts KE, Rey F, Agostini I et al.: DNA repair enzyme uracil DNA glycosylase is specifically incorporated into human immunodeficiency virus type 1 viral particles through a Vpr-independent mechanism. J. Virol. 73(2), 1682-1688 (1999).
108. Bouhamdan M, Benichou S, Rey F et al.: Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J. Virol. 70(2), 697-704 (1996). □□ Vpr interacts with UNG2, the DNA glycosylase that ensures the initial step of uracil excision and DNA repair by the BER pathway. In the complex, UNG2 retains its capacity to excise uracil from DNA. This interaction probably directs the viral incorporation of UNG2.
109. Selig L, Benichou S, Rogel ME et al.: Uracil DNA glycosylase specifically interacts with Vpr of both human immunodeficiency virus type 1 and simian immunodeficiency virus of sooty mangabeys, but binding does not correlate with cell cycle arrest. J. Virol. 71(6), 4842-4846 (1997).
110. Sleigh R, Sharkey M, Newman MA, Hahn B, Stevenson M: Differential association of uracil DNA glycosylase with sivsm Vpr and Vpx proteins. Virology 245(2), 338-343 (1998).
111. Mansky LM, Preveral S, Selig L, Benarous R, Benichou S: The interaction of Vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 in vivo mutation rate. J. Virol. 74(15), 7039-7047 (2000).
112. Chen R, Le Rouzic E, Kearney JA, Mansky LM, Benichou S: Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages. J. Biol. Chem. 279(27), 28419-28425 (2004).
113. Schrofelbauer B, Yu Q, Zeitlin SG, Landau NR: Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J. Virol. 79(17), 10978-10987 (2005).
114. Priet S, Navarro JM, Gros N, Querat G, Sire J: Differential incorporation of uracil DNA glycosylase UNG2 into HIV-1, HIV-2, and SIV (mac) viral particles. Virology 307(2), 283-289 (2003).
115. Priet S, Navarro JM, Gros N, Querat G, Sire J: Functional role of HIV-1 virionassociated uracil DNA glycosylase 2 in the correction of G:U mispairs to G:C pairs. J. Biol. Chem. 278(7), 4566-4571 (2003). □ Incorporation of UNG2 in HIV-1 particles is essential to the viral lifecycle. Together with UNG2 packaged within viruses, the viral reverse transcriptase fulfills in vitro a BER-like function. Virus-associated UNG2 may, thus, play a pivotal role to control accumulation of uracil in the viral genome during early infection.
116. Priet S, Gros N, Navarro JM et al.: HIV-1-associated uracil DNA glycosylase activity controls dUTP misincorporation in viral DNA and is essential to the HIV-1 life cycle. Mol. cell 17(4), 479-490 (2005).
117. Kaiser SM, Emerman M: Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 80(2), 875-882 (2006).
118. Yang B, Chen K, Zhang C, Huang S, Zhang H: Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 282(16), 11667-11675 (2007).
119. Fenard D, Houzet L, Bernard e et al.: Uracil DNA glycosylase 2 negatively regulates HIV-1 LTR transcription. Nucleic Acids Res. 37(18), 6008-6018 (2009). □ UNG2 expression in the infected cell represses HIV-1 gene transcription. This uracil DNA glycosylase is likely to represent a host defense factor specifically counteracted by Vpr. Thus, interaction of UNG2 with Vpr has different outcomes: packaging of a benefcial cellular compound in virions, and counteracting a detrimental antiviral factor in the cell cytoplasm.
120. Schrofelbauer B, Hakata Y, Landau NR: HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc. Natl Acad. Sci. USA 104(10), 4130-4135 (2007). □□ In the infected cell, Vpr targets UNG2 to the proteasome by recruiting the DDB1-Cul4-Roc1 E3 ligase complex.
121. Dehart JL, Planelles V: Human immunodeficiency virus type 1 Vpr links proteasomal degradation and checkpoint activation. J. Virol. 82(3), 1066-1072 (2008).
122. Langevin C, Maidou-Peindara P, Aas PA et al.: Human immunodeficiency virus type 1 Vpr modulates cellular expression of UNG2 via a negative transcriptional effect. J. Virol. 83(19), 10256-10263 (2009).
123. Hagen L, Kavli B, Sousa MM et al.: Cell cycle-specific UNG2 phosphorylations regulate protein turnover, activity and association with RPA. EMBO J. 27(1), 51-61 (2008).
124. Haug T, Skorpen F, Aas PA, Malm V, Skjelbred C, Krokan HE: Regulation of expression of nuclear and mitochondrial forms of human uracil-DNA glycosylase. Nucleic Acids Res. 26(6), 1449-1457 (1998).
125. Sheehy AM, Gaddis NC, Malim MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9(11), 1404-1407 (2003).
126. Van Damme N, Guatelli J: HIV-1 Vpu inhibits accumulation of the envelope glycoprotein within clathrin-coated, Gag-containing endosomes. Cell Microbiol. 10(5), 1040-1057 (2008).
127. Jones KL, Roche M, Gantier MP et al.: X4 and r5 HIV-1 have distinct post-entry requirements for uracil DNA glycosylase during infection of primary cells. J. Biol. Chem. 285(24), 18603-18614 (2010).
128. Withers-Ward ES, Jowett JB, Stewart SA et al.: Human immunodeficiency virus type 1 Vpr interacts with HHR23A, a cellular protein implicated in nucleotide excision DNA repair. J. Virol. 71(12), 9732-9742 (1997).
129. Withers-Ward ES, Mueller TD, Chen IS, Feigon J: Biochemical and structural analysis of the interaction between the UBA (2) domain of the DNA repair protein HHR23A and HIV-1 Vpr. Biochemistry 39(46), 14103-14112 (2000).
130. Kino T, Gragerov A, Valentin A et al.: Vpr protein of human immunodeficiency virus type 1 binds to 14-3-3 proteins and facilitates complex formation with CDC25C: implications for cell cycle arrest. J. Virol. 79(5), 2780-2787 (2005).
131. Mansky LM, Preveral S, Le Rouzic E et al.: Interaction of human immunodeficiency virus type 1 Vpr with the HHR23A DNA repair protein does not correlate with multiple biological functions of Vpr. Virology 282(1), 176-185 (2001).
132. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR: Human immunodeficiency virus type 1 viral protein r (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34CDC2 activity. J. Virol. 69(11), 6705-6711 (1995).
133. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS: The human immunodeficiency virus type 1 Vpr gene arrests infected t cells in the G2 + M phase of the cell cycle. J. Virol. 69(10), 6304-6313 (1995).
134. Rogel ME, Wu LI, Emerman M: The human immunodeficiency virus type 1 Vpr gene prevents cell proliferation during chronic infection. J. Virol. 69(2), 882-888 (1995).
135. Zimmerman ES, Sherman MP, Blackett JL et al.: Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J. Virol. 80(21), 10407-10418 (2006).
136. Zhao Y, Cao J, O'Gorman MR, Yu M, Yogev R: Effect of human immunodeficiency virus type 1 protein r (Vpr) gene expression on basic cellular function of fission yeast Schizosaccharomyces pombe. J. Virol. 70(9), 5821-5826 (1996).
137. Fukasawa K: Oncogenes and tumour suppressors take on centrosomes. Nat. Rev. Cancer 7(12), 911-924 (2007).
138. Angers S, Li T, Yi X, Maccoss MJ, Moon RT, Zheng N: Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443(7111), 590-593 (2006).
139. Zhao LJ, Mukherjee S, Narayan O: Biochemical mechanism of HIV-I Vpr function. Specific interaction with a cellular protein. J. Biol. Chem. 269(22), 15577-15582 (1994).
140. Dehart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, Planelles V: HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol. J. 4, 57 (2007).
141. Hrecka K, Gierszewska M, Srivastava S et al.: Lentiviral Vpr usurps CUL4-DDB1[Vprbp] E3 ubiquitin ligase to modulate cell cycle. Proc. Natl Acad. Sci. USA 104(28), 11778-11783 (2007).
142. Le Rouzic E, Belaidouni N, Estrabaud e et al.: HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VPRBP, a receptor of the CUL4-DDB1 ubiquitin ligase. Cell cycle (Georgetown, Tex.) 6(2), 182-188 (2007). □ Shows that Vpr recruits the Vpr binding protein DCAF1 to induce G2/M arrest of the cell cycle.
143. Wen X, Duus KM, Friedrich TD, De Noronha CM: The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and CULLIN4A-containing ubiquitin ligase complex using Vprbp/DCAF1 as an adaptor. J. Biol. Chem. 282(37), 27046-27057 (2007).
144. Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, Cohen EA: HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVprbp E3 ubiquitin ligase. PLoS Pathogens 3(7), e85 (2007). □□ Vpr arrests cells at the DNA damage checkpoint in the G2 phase of the cell cycle. This effect relies on the capacity of Vpr to connect the DDB1-Cull4-E3 ubiquitin ligase complex to an unknown factor. Ubiquitinylation and degradation of the factor would activate ATR-mediated checkpoint signaling and induce G2 arrest.
145. Tan L, Ehrlich E, Yu XF: DDB1 and Cul4a are required for human immunodeficiency virus type 1 Vpr-induced GF2 arrest. J. Virol 81(19), 10822-10830 (2007).
146. Casey L, Wen X, De Noronha CM: The functions of the HIV1 protein Vpr and its action through the DCAF1. DDB1. Cullin4 ubiquitin ligase. Cytokine 51(1), 1-9 (2010).
147. Huang J, Chen J: Vprbp targets merlin to the Roc1-Cul4a-DDB1 E3 ligase complex for degradation. Oncogene 27(29), 4056-4064 (2008).
148. Belzile JP, Richard J, Rougeau N, Xiao Y, Cohen EA: HIV-1 Vpr induces the K48-linked polyubiquitination and proteasomal degradation of target cellular proteins to activate ATR and promote G2 arrest. J. Virol. 84(7), 3320-3330 (2010).
149. Zhao RY, Elder RT, Bukrinsky M: Interactions of HIV-1 viral protein r with host cell proteins. Advances Pharmacol. (San Diego, Calif.) 55, 233-260 (2007).
150. Bartz SR, Rogel ME, Emerman M: Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J. Virol. 70(4), 2324-2331 (1996).
151. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V: Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein r. J. Biol. Chem. 278(28), 25879-25886 (2003). □□ HIV-1 Vpr protein blocks cellular proliferation by activating ATR and modulating the ATR-initiated DNA damage signaling pathway.
152. Lai M, Zimmerman ES, Planelles V, Chen J: Activation of the ATR pathway by human immunodeficiency virus type 1 Vpr involves its direct binding to chromatin in vivo. J. Virol. 79(24), 15443-15451 (2005).
153. Li G, Elder RT, Qin K, Park HU, Liang D, Zhao RY: Phosphatase type 2a-dependent and-independent pathways for ATR phosphorylation of CHK1. J. Biol. Chem. 282(10), 7287-7298 (2007).
154. Zimmerman ES, Chen J, Andersen JL et al.: Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and γ-H2AX focus formation. Mol. Cell. Biol. 24(21), 9286-9294 (2004). □□ Vpr-induced G2 arrest retains characteristics of DNA damage. This includes activation of a Rad17-, Hus1-dependent signaling pathway, generally activated upon replication stress and the formation of γ-H2AX and BRCA1 nuclear foci, characteristic markers of DNA damage.
155. Tachiwana H, Shimura M, Nakai-Murakami C et al.: HIV-1 Vpr induces DNA double-strand breaks. Cancer Res. 66(2), 627-631 (2006).
156. Chu G, Chang E: Xeroderma pigmentosum group e cells lack a nuclear factor that binds to damaged DNA. Science 242(4878), 564-567 (1988).
157. Yuan H, Kamata M, Xie YM, Chen IS: Increased levels of Wee-1 kinase in G (2) are necessary for Vpr-and γ irradiation-induced G (2) arrest. J. Virol. 78(15), 8183-8190 (2004).
158. Goh WC, Manel N, Emerman M: The human immunodeficiency virus Vpr protein binds CDC25C: implications for G2 arrest. Virology 318(1), 337-349 (2004).
159. Kamata M, Watanabe N, Nagaoka Y, Chen IS: Human immunodeficiency virus type 1 Vpr binds to the N lobe of the Wee1 kinase domain and enhances kinase activity for CDC2. J. Virol. 82(12), 5672-5682 (2008).
160. Bolton DL, Barnitz RA, Sakai K, Lenardo MJ: 14-3-3 τ binding to cell cycle regulatory factors is enhanced by HIV-1 Vpr. Biology Direct 3, 17 (2008).
161. Wang Y, Jacobs C, Hook KE, Duan H, Booher RN, Sun Y: Binding of 14-3-3β to the carboxyl terminus of Wee1 increases Wee1 stability, kinase activity, and G2-M cell population. Cell Growth Differ. 11(4), 211-219 (2000).
162. Hashizume C, Kuramitsu M, Zhang X, Kurosawa T, Kamata M, Aida Y: Human immunodeficiency virus type 1 Vpr interacts with spliceosomal protein sap145 to mediate cellular pre-mRNA splicing inhibition. Microbes Infect./Institut. Pasteur. 9(4), 490-497 (2007).
163. Terada Y, Yasuda Y: Human immunodeficiency virus type 1 Vpr induces G2 checkpoint activation by interacting with the splicing factor sap145. Mol. Cell. Biol. 26(21), 8149-8158 (2006).
164. Zander K, Sherman MP, Tessmer U et al.: Cyclophilin a interacts with HIV-1 Vpr and is required for its functional expression. J. Biol. Chem. 278(44), 43202-43213 (2003).
165. Ardon O, Zimmerman ES, Andersen JL, Dehart JL, Blackett J, Planelles V: Induction of G2 arrest and binding to cyclophilin a are independent phenotypes of human immunodeficiency virus type 1 Vpr. J. Virol. 80(8), 3694-3700 (2006).
166. Goh WC, Rogel ME, Kinsey CM et al.: HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat. Med. 4(1), 65-71 (1998). □□ Cell cycle arrest at the G2 phase of the cell cycle ensures optimal LTR-driven gene transcription and viral production.
167. Brasey A, Lopez-Lastra M, Ohlmann T et al.: The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J. Virol. 77(7), 3939-3949 (2003).
168. Hrimech M, Yao XJ, Bachand F, Rougeau N, Cohen EA: Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. J. Virol. 73(5), 4101-4109 (1999).
169. Poon B, Jowett JB, Stewart SA, Armstrong RW, Rishton GM, Chen IS: Human immunodeficiency virus type 1 Vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard. J. Virol. 71(5), 3961-3971 (1997).
170. Patel CA, Mukhtar M, Pomerantz RJ: Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J. Virol. 74(20), 9717-9726 (2000).
171. Deniaud A, Brenner C, Kroemer G: Mitochondrial membrane permeabilization by HIV-1 Vpr. Mitochondrion 4 (2-3), 223-233 (2004).
172. Jian H, Zhao LJ: Pro-apoptotic activity of HIV-1 auxiliary regulatory protein Vpr is subtype-dependent and potently enhanced by nonconservative changes of the leucine residue at position 64. J. Biol. Chem. 278(45), 44326-44330 (2003).
173. Muthumani K, Hwang DS, Desai Bm et al.: HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J. Biol. Chem. 277(40), 37820-37831 (2002).
174. Jacotot E, Ferri KF, El Hamel C et al.: Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein r and BCL-2. J. Exp. Med. 193(4), 509-519 (2001).
175. Jacotot E, Ravagnan L, Loeffler M et al.: The HIV-1 viral protein r induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J. Exp. Med. 191(1), 33-46 (2000).
176. 3-expressing endothelial cells. Cell Death Differ. 14(3), 422-435 (2007).
177. Sabbah EN, Druillennec S, Morellet N, Bouaziz S, Kroemer G, Roques BP: Interaction between the HIV-1 protein Vpr and the adenine nucleotide translocator. Chem. Biol. Drug Des. 67(2), 145-154 (2006).
178. Andersen JL, Dehart JL, Zimmerman ES et al.: HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires BAX but not ANT. PLoS Pathogens 2(12), e127 (2006).
179. Yedavalli VS, Shih HM, Chiang YP et al.: Human immunodeficiency virus type 1 Vpr interacts with antiapoptotic mitochondrial protein HAX-1. J. Virol. 79(21), 13735-13746 (2005).